Emergent BioSolutions
EBS
#6906
Rank
โ‚ฌ0.50 B
Marketcap
9,55ย โ‚ฌ
Share price
-4.71%
Change (1 day)
-6.68%
Change (1 year)

Revenue for Emergent BioSolutions (EBS)

Revenue in 2025 (TTM): โ‚ฌ0.67 Billion

According to Emergent BioSolutions 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ0.63 Billion. In 2024 the company made a revenue of โ‚ฌ0.97 Billion an increase over the revenue in the year 2023 that were of โ‚ฌ0.92 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Emergent BioSolutions from 2004 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ0.67 B-30.71%
2024 โ‚ฌ0.97 B5.26%
2023 โ‚ฌ0.92 B-8.04%
2022 โ‚ฌ1.00 B-31.29%
2021 โ‚ฌ1.46 B25.06%
2020 โ‚ฌ1.17 B33.38%
2019 โ‚ฌ0.87 B42.4%
2018 โ‚ฌ0.61 B50.83%
2017 โ‚ฌ0.40 B24.47%
2016 โ‚ฌ0.32 B-8.74%
2015 โ‚ฌ0.35 B28.99%
2014 โ‚ฌ0.27 B49.37%
2013 โ‚ฌ0.18 B45.21%
2012 โ‚ฌ0.12 B-38.9%
2011 โ‚ฌ0.21 B-2.15%
2010 โ‚ฌ0.21 B31.29%
2009 โ‚ฌ0.16 B28.31%
2008 โ‚ฌ0.12 B1.95%
2007 โ‚ฌ0.12 B-4.43%
2006 โ‚ฌ0.13 B18.81%
2005 โ‚ฌ0.11 B79.24%
2004 โ‚ฌ61.55 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Pfizer
PFE
โ‚ฌ52.89 B 8,263.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
โ‚ฌ54.11 B 8,456.68%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚ฌ35.67 B 5,541.77%๐Ÿ‡ฌ๐Ÿ‡ง UK
Soligenix
SNGX
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
SIGA Technologies
SIGA
โ‚ฌ0.14 B-77.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚ฌ2.19 M-99.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ14.13 B 2,134.71%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel